Total Payments
$1,237
2024 Payments
$128.84
Companies
22
Transactions
50
Medicare Patients
104,194
Medicare Billing
$14.2M
Payment Breakdown by Category
Food & Beverage$1,225 (99.0%)
Education$11.92 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,225 | 49 | 99.0% |
| Education | $11.92 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sirtex Medical Inc | $245.75 | 5 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $134.67 | 8 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $131.43 | 2 | $0 (2021) |
| Intera Oncology, Inc | $128.84 | 1 | $0 (2024) |
| Kite Pharma, Inc. | $112.90 | 7 | $0 (2022) |
| EISAI INC. | $72.47 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $54.01 | 3 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $49.68 | 2 | $0 (2018) |
| Mylan Institutional Inc. | $46.41 | 2 | $0 (2020) |
| PFIZER INC. | $36.77 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $128.84 | 1 | Intera Oncology, Inc ($128.84) |
| 2023 | $14.88 | 1 | Kerecis Limited ($14.88) |
| 2022 | $320.07 | 9 | Sirtex Medical Inc ($228.13) |
| 2021 | $263.19 | 10 | AstraZeneca Pharmaceuticals LP ($131.43) |
| 2020 | $74.41 | 4 | Mylan Institutional Inc. ($24.13) |
| 2019 | $113.43 | 6 | Merck Sharp & Dohme Corporation ($39.14) |
| 2018 | $269.16 | 16 | Novartis Pharmaceuticals Corporation ($118.05) |
| 2017 | $52.84 | 3 | Bayer HealthCare Pharmaceuticals Inc. ($23.61) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/08/2024 | Intera Oncology, Inc | INTERA (Device) | Food and Beverage | In-kind items and services | $128.84 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2023 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 GraftGuide, Kerecis Omega3 SurgiClose | Food and Beverage | Cash or cash equivalent | $14.88 | General |
| Category: Wound Care | ||||||
| 11/09/2022 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Hematology | ||||||
| 10/11/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $14.61 | General |
| Category: Interventional Oncology | ||||||
| 09/28/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/06/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $17.10 | General |
| Category: Interventional Oncology | ||||||
| 08/30/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.21 | General |
| 08/24/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/02/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $180.84 | General |
| Category: Interventional Oncology | ||||||
| 02/23/2022 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $15.58 | General |
| Category: Interventional Oncology | ||||||
| 01/19/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $16.61 | General |
| 08/02/2021 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Genetic Disease | ||||||
| 06/24/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.78 | General |
| 06/22/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $19.87 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/20/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $12.77 | General |
| 05/10/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $11.22 | General |
| 04/27/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $122.26 | General |
| Category: Oncology | ||||||
| 04/15/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $9.17 | General |
| Category: Oncology | ||||||
| 01/18/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $16.86 | General |
| 07/25/2020 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: Interventional Oncology | ||||||
| 07/15/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.79 | General |
| 03/05/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2020 | Mylan Institutional Inc. | Ogivri (Biological), Fulphila | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 123 | 28,765 | 335,732 | $14.3M | $3.3M |
| 2022 | 137 | 27,150 | 467,564 | $18.5M | $4.0M |
| 2021 | 128 | 26,719 | 460,310 | $17.3M | $3.5M |
| 2020 | 117 | 21,560 | 372,169 | $14.7M | $3.4M |
Total Patients
104,194
Total Services
1,635,775
Medicare Billing
$14.2M
Procedure Codes
505
All Medicare Procedures & Services
505 procedure records from CMS Medicare Utilization — Page 1 of 21
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 42 | 23,400 | $2.3M | $1.0M | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,355 | 2,531 | $1.2M | $287,206 | 24.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 83 | 15,420 | $1.4M | $279,963 | 20.3% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 9,360 | $561,600 | $211,933 | 37.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 142 | 156,000 | $780,000 | $134,861 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 428 | 807 | $758,580 | $132,706 | 17.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 14 | 3,470 | $381,700 | $115,450 | 30.2% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 179 | 4,360 | $470,880 | $101,345 | 21.5% |
| J2796 | Injection, romiplostim, 10 micrograms | Office | 2023 | 11 | 1,300 | $312,000 | $93,585 | 30.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 481 | 1,640 | $245,925 | $90,513 | 36.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 185 | 554 | $304,700 | $71,004 | 23.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 31 | 24,300 | $486,000 | $56,741 | 11.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 333 | 494 | $187,720 | $54,151 | 28.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 48 | 144 | $302,400 | $48,360 | 16.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 2,253 | 5,089 | $101,780 | $42,622 | 41.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 1,959 | 4,045 | $242,700 | $41,667 | 17.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 2,112 | 4,919 | $737,850 | $37,279 | 5.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 228 | 482 | $240,500 | $29,922 | 12.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 1,178 | 2,035 | $305,250 | $27,004 | 8.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 124 | 124 | $96,720 | $24,659 | 25.5% |
| 83735 | Magnesium level | Office | 2023 | 1,485 | 3,034 | $227,550 | $19,794 | 8.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 203 | 221 | $66,300 | $18,594 | 28.0% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 1,457 | 2,972 | $89,160 | $17,502 | 19.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 544 | 1,376 | $261,440 | $17,494 | 6.7% |
| 83550 | Iron binding capacity | Office | 2023 | 1,097 | 1,892 | $236,500 | $16,095 | 6.8% |
About Dr. Roy Chen, MD
Dr. Roy Chen, MD is a Hematology & Oncology healthcare provider based in Riverhead, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1720248081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Chen, MD has received a total of $1,237 in payments from pharmaceutical and medical device companies, with $128.84 received in 2024. These payments were reported across 50 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,225).
As a Medicare-enrolled provider, Chen has provided services to 104,194 Medicare beneficiaries, totaling 1,635,775 services with total Medicare billing of $14.2M. Data is available for 4 years (2020–2023), covering 505 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Riverhead, NY
- Active Since 06/11/2008
- Last Updated 02/03/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1720248081
Products in Payments
- SIR-Spheres Microspheres (Device) $245.75
- CALQUENCE (Drug) $131.43
- INTERA (Device) $128.84
- Lenvima (Drug) $72.47
- JADENU (Drug) $64.10
- KEYTRUDA (Biological) $54.01
- XARELTO (Drug) $49.68
- RYDAPT (Drug) $48.76
- Ogivri (Biological) $46.41
- VYNDAQEL (Drug) $36.77
- FARESTON (Drug) $34.97
- Vonjo (Drug) $24.35
- Aliqopa (Drug) $23.61
- GIVLAARI (Drug) $22.46
- MEKINIST (Drug) $21.81
- TIBSOVO (Drug) $18.88
- JEVTANA (Drug) $17.65
- Kerecis Omega3 SurgiClose (Device) $14.88
- Zevalin (Drug) $12.61
- BENDEKA (Drug) $12.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.